Hypothesis

NAD+ availability does not merely reflect metabolic state; it actively sets the threshold for OSK‑driven epigenetic reprogramming by controlling α‑ketoglutarate‑dependent TET enzyme activity. When NAD+ falls, the TET‑mediated demethylation cascade slows, requiring more frequent or higher‑dose OSK pulses to achieve the same epigenetic age reversal. Conversely, raising NAD+ accelerates TET action, allowing fewer OSK pulses to reach a target methylation state and reducing the risk of over‑reprogramming.

Mechanistic Rationale

OSK factors recruit TET1/2 to demethylate age‑associated CpG sites [4]. TET enzymes require α‑ketoglutarate (α‑KG) as a co‑factor and are inhibited by succinate and fumarate, metabolites whose ratios are shaped by NAD+‑dependent TCA‑cycle flux. NAD+ stimulates the activity of dehydrogenases (e.g., isocitrate dehydrogenase) that generate α‑KG, while NADH favors reductive pathways where succinate accumulates. Thus, a high NAD+/NADH ratio pushes the TCA cycle toward oxidative production of α‑KG, boosting TET catalysis. In addition, NAD+‑dependent sirtuins (SIRT1, SIRT6) deacetylate histone tails, increasing chromatin accessibility for OSK binding and TET recruitment.

When NAD+ declines with age, α‑KG production drops and succinate rises, dampening TET activity. The cell then perceives the epigenetic landscape as "locked," making OSK‑induced demethylation less efficient. To compensate, the system would need stronger or more frequent OSK stimuli, which pushes the regimen toward the continuous expression regime that raises tumorigenic risk.

Predictions & Experimental Design

1. Kinetic prediction – In aged mice, cyclic OSK (2‑day ON/5‑day OFF) combined with NAD+ booster (nicotinamide riboside, NR) will achieve a 30 % greater reduction in epigenetic age (as measured by PC1‑based clock) after 4 weeks compared with OSK alone, while using half the number of ON days.
2. Dose‑shift prediction – NR‑treated animals will require only weekly 1‑day ON/6‑day OFF to reach the same epigenetic age reversal that control animals need with the standard 2‑day ON/5‑day OFF schedule.
3. Mechanistic blockade – Genetic knockdown of Tet1/2 in liver will abolish the synergistic effect of NR on OSK‑mediated demethylation, confirming TET dependence.
4. Safety read‑out – Continuous OSKM expression in NR‑supplemented mice will not increase teratoma incidence beyond baseline, indicating that the NAD+‑mediated shift does not remove the need for transient dosing.

Experimental groups (n = 10 per group):

• OSK alone (standard 2‑day ON/5‑day OFF)
• OSK + NR (same OSK schedule)
• OSK + NR (reduced 1‑day ON/6‑day OFF)
• OSK + Tet1/2 shRNA (standard schedule)
• OSK + NR + Tet1/2 shRNA (standard schedule)
• Control (AAV‑GFP)

Measurements: longitudinal blood‑based methylation clocks, hepatic α‑KG/succinate ratios (LC‑MS), TET activity assays, histology for dysplasia, and functional assays (glucose tolerance, grip strength).

Potential Outcomes

If the NR‑OSK synergy is observed, the hypothesis is supported: NAD+ levels modulate the epigenetic competence of OSK factors via TET‑dependent demethylation, enabling personalized, biomarker‑guided dosing (e.g., adjusting OSK pulse frequency according to circulating NAD+ or α‑KG/succinate ratio). If NR fails to alter OSK kinetics or Tet1/2 knockdown does not affect the outcome, the hypothesis is falsified, suggesting that NAD+ influences aging through pathways independent of TET‑mediated epigenetic reprogramming.

This work bridges the NAD+ budget‑cut metaphor with a concrete enzymatic link, offering a rationally tunable strategy to extend the therapeutic window of partial reprogramming.